Home/Pipeline/Antibody Drug Conjugates (ADCs)

Antibody Drug Conjugates (ADCs)

Oncology

Pre-clinicalActive

Key Facts

Indication

Oncology

Phase

Pre-clinical

Status

Active

Company

nCage Therapeutics

About nCage Therapeutics

nCage Therapeutics is an early-stage biotech leveraging its proprietary TRAP-cage platform to design synthetic virus-like particles for vaccine and drug delivery applications. The platform's key differentiators include programmable opening/closing for cargo loading and the ability to display biomolecules in precise arrays. The company is advancing preclinical programs in respiratory vaccines and oncology ADCs, supported by strategic collaborations with academia and industry partners like MSD. As a private, pre-revenue entity, nCage is building a foundation of intellectual property and proof-of-concept data to attract further partnership and investment.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other Oncology Drugs

Drug	Company	Phase	Status
Bi-XDC with PROTACs	Coherent Biopharma	IND-enabling	Active
Bi-XDC with RPT	Coherent Biopharma	Early-stage	Active
mRNA Anticancer Vaccine	Sunshine Biopharma	Preclinical Research	Active
Biosimilar Bevacizumab	Organon (2)	Phase 3	Active
Biosimilar Pembrolizumab	Organon (2)	Phase 3	Active
BCL-2 Inhibitor Program	Vincerx Pharma	Preclinical	Research
Not specified in provided content	3Sbio	Various	Active
Preclinical Projects	Zion Pharma	Preclinical	Active
Attenukine Oncology Candidate	Teva	Phase 1	Active
XEMA Tumor Marker ELISA Kit	XEMA Group	Commercial	Active
KRAS inhibitor	Risen Pharma Tech	Preclinical/Phase 1	Active (AACR 2024 presentation)
KEAP1 Activator Program	Vividion Therapeutics	Phase 1	Active